Waldenström macroglobulinemia

Béla Telek, Péter Batár, László Váróczy, Lajos Gergely, László Rejto, Róbert Szász, Zsófia Miltényi, Zsófia Simon, Miklós Udvardy, Árpád Illés

Research output: Contribution to journalArticle


Waldenström macroglobulinemia is a rare lymphoproliferative disease of B-cell origin.These tumorous B-cells produce monoclonal IgM type protein. Diagnosis is based on the detection of lymphoplasmacytic invasion of the bone marrow and serum electrophoresis. Clinical symptoms such as anemia, hyperviscosity and neuropathy are the commom consequences of bone marrow infiltration and serum monoclonal IgM protein. Former use of alkylating agents are replaced by purine analogues, rituximab and bortezomib. Additional clinical data have also accumulated regarding autologous and allogenous stem-cell transplantation. The authors present their own clinical experience and give a detailed review of current therapeutic approaches. Orv. Hetil., 154(50), 1970-1974.

Original languageEnglish
Pages (from-to)1970-1974
Number of pages5
JournalOrvosi hetilap
Issue number50
Publication statusPublished - Dec 1 2013


  • Chemoimmunotherapy
  • Fludarabine
  • Lymphoplasmacytic cells
  • Monoclonal IgM protein
  • Rituximab
  • Stem-cell transplantation

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Waldenström macroglobulinemia'. Together they form a unique fingerprint.

  • Cite this

    Telek, B., Batár, P., Váróczy, L., Gergely, L., Rejto, L., Szász, R., Miltényi, Z., Simon, Z., Udvardy, M., & Illés, Á. (2013). Waldenström macroglobulinemia. Orvosi hetilap, 154(50), 1970-1974. https://doi.org/10.1556/OH.2013.29776